Beam shares results from seven patients who received gene-edited sickle cell therapy

Lei Lei Wu

News Reporter

SAN DIEGO — Beam Therapeutics now has trial data from seven patients who have received its gene-edited sickle cell therapy, showing promising early signs that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Beam shares results from seven patients who received gene-edited sickle cell therapy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

Judge halts some NIH cuts after 22 states sue

Vertex operations chief Stuart Arbuckle to retire

Merck KGaA confirms interest in acquiring cancer biotech SpringWorks

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Beam shares results from seven patients who received gene-edited sickle cell therapy